Heilongjiang ZBD Pharmaceutical Co Ltd (603567) Valuation & Financial Model
Interactive Discounted Cash Flow (DCF) model for Heilongjiang ZBD Pharmaceutical Co Ltd (SSE:603567), currently being evaluated. In 2025, Heilongjiang ZBD Pharmaceutical Co Ltd generated $798.06 Million in revenue and $253.57 Million in free cash flow. Explore projected intrinsic value assumptions based on institutional-grade macro metrics.
Valuation Methodology & Recent Performance
The financial model for Heilongjiang ZBD Pharmaceutical Co Ltd is calculated using an institutional discounted cash flow (DCF) engine utilizing recent operational metrics:
- Current Price: N/A
- Recent Revenue (2025): $798.06 Million
- Free Cash Flow (2025): $253.57 Million
- Discount Rate (WACC): Derived using the Risk-Free Rate (e.g., 10Y Gov Bond) plus an Equity Risk Premium based on market volatility and stock price variance.
- Terminal Value: Projected using a perpetual growth model bounded by long-term macroeconomic estimates.